Evaluating NGGT003 for treating Hemophilia A

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This early phase 1, open-label, single-center pilot trial aims to assess the safety and efficacy of NGGT003, an intravenous infusion designed for hemophilia A patients. The study utilizes an adeno-associated virus (AAV) vector to deliver a modified human FVIII gene to the liver, potentially enabling the production of the FVIII protein. A total of 4-6 male participants aged 18 and older will be enrolled, receiving escalating doses of NGGT003, with a follow-up period extending up to 260 weeks to monitor long-term effects.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Voluntarily sign the informed consent form;
2. Male, age ≥18 years old;
3. Diagnosed with hemophilia A according to the "Guidelines for Diagnosis and Treatment of Hemophilia A (2022 Edition)", and the endogenous FVIII activity level was \<1 IU/dL (\<1%);
4. The exposure days (EDs) of treatment with any recombinant or plasma-derived FVIII product were ≥150 days;
5. Anti-AAV neutralizing antibody titer ≤1:5, binding antibody titer ≤1:100;
6. Bleeding events and/or FVIII product injections have occurred within 12 weeks before screening;
7. No history of allergy to FVIII products;
8. FVIII inhibitor titer﹤0.6BU/mL;
9. Commitment to use other drugs during the study requires the consent of the investigator;
10. Willing and able to comply with study procedures and requirements;
11. Willing to use effective contraceptive methods within 52 weeks after administration.

Exclusion Criteria:

1. Positive for hepatitis B surface antigen, hepatitis C, human immunodeficiency virus (HIV)，syphilis test;
2. Clinically significant abnormalities in liver function test: alanine aminotransferase (ALT) \>1.5 × upper limit of normal (ULN) and/or aspartate aminotransferase (AST) \>1.5× ULN;TBil）\>1.5×ULN；Serum creatinine (Scr) \>1.5×ULN; hemoglobin \<110g/L, platelets \<10e9/L;
3. History of being positive for FVIII inhibitors;
4. Have other bleeding factors except hemophilia;
5. Plan major surgery within 52 weeks;
6. Have contraindications to glucocorticoid, including but not limited to allergy to glucocorticoids, epilepsy, new unhealed fractures, in trauma repair period, uncontrolled infection, severe osteoporosis, etc, which assessed and determined by the investigators;
7. History of allergy to human albumin;
8. Have serious diseases or active infections in cardiovascular, respiratory, digestive tract, endocrine, renal, blood, nervous, mental and other systems before screening;
9. With hepatitis, cirrhosis, liver cancer or other major liver diseases;
10. History of malignant tumors;
11. Abnormal and clinical significant vital signs, physical examination, laboratory examination or other related examination results during the screen, which are not suitable for trial according to the investigator;
12. Previous gene therapy treatment;
13. Participation in any other clinical trial before the screening and have taken medication within four weeks or five half-lives of the study drug;
14. Any other condition that may not be appropriate for the study in the opinion of the investigator.

Where it's running

• Institute of Hematology & Blood Diseases Hospital
  Tianjin, Tianjin Municipality, China Recruiting

Study contacts

• Principal investigator: Lei Zhang, MD — Institute of Hematology & Blood Diseases Hospital, China
• Study coordinator: Wei Liu, MD
• Email: liuwei1@ihcams.ac.cn
• Phone: +862223909240

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• First‑in‑human test of ARD001 in healthy adults and people with hemophilia A

  This study tests ARD001 to see if it is safe and tolerable in healthy adults and in people with hemophilia A, using a single dose (Phase 1) and potentially repeated doses (Phase 2) if results look good.

  Recruiting Phase 1/2 Arditus Pte Ltd · Singapore · NCT07787091

• Hemophilia A: comparing long-acting FVIII replacement vs non-FVIII therapy in kids

  This study tests whether children with moderate to severe Hemophilia A on long-acting FVIII or non-FVIII therapies form clots differently and develop small joint bleeds or early joint changes.

  Recruiting University of Texas Southwestern Medical Center · Dallas, Texas · NCT07692217

• SR604: a new treatment tested in adults with Hemophilia A/B or congenital Factor VII deficiency

  This study tests a single and multiple doses of SR604 to see if it is safe and effective for adults with Hemophilia A or B, with or without inhibitors, and for those with congenital Factor VII deficiency.

  Recruiting at 7 sites Phase 1/2 Shanghai RAAS Blood Products Co., Ltd. · Changsha and 8 other locations · NCT07644832

• Bone health in severe hemophilia A: emicizumab vs efanesoctocog alfa

  This study tests whether bone density and bone health markers differ in adults with severe hemophilia A who use emicizumab versus efanesoctocog alfa for prophylaxis.

  Recruiting Arkansas Children's Hospital Research Institute · Little Rock, Arkansas · NCT07582276

• Joint health, balance, and quality of life in adults with hemophilia A

  See how joint damage and postural balance relate to quality of life in adults with severe hemophilia A.

  Recruiting Yuzuncu Yil University · Van · NCT07523399

• NXT007 versus emicizumab to prevent bleeds in people with Hemophilia A

  This will test whether NXT007 prevents bleeding better than emicizumab in people aged 12 and older with Hemophilia A, including those with or without factor VIII inhibitors.

  Recruiting at 63 sites Phase 3 Hoffmann-La Roche · Orange, California and 62 other locations · NCT07416604

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.